BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sundaram V, Kowdley KV. Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection. Hepat Med 2016;8:75-80. [PMID: 27418860 DOI: 10.2147/HMER.S63125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag 2017;13:477-97. [PMID: 28442915 DOI: 10.2147/TCRM.S134818] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yamazhan T, Turan İ, Ersöz G, Günşar F, Pullukçu H, Danış N, Ünal NG, Vardar R, Oruç N, Tekin F, Taşbakan M, Sipahi OR, Akarca US. Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey. Turk J Gastroenterol 2020;31:239-45. [PMID: 32343236 DOI: 10.5152/tjg.2020.19076] [Reference Citation Analysis]
3 Nagral A, Sawant S, Nagral N, Parikh P, Malde P, Merchant R. Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major. J Clin Exp Hepatol 2017;7:172-8. [PMID: 28970702 DOI: 10.1016/j.jceh.2017.08.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
4 Joglekar K, Eason JD, Molnar MZ. Do we really need more evidence to use hepatitis C positive donor kidney more liberally? Clin Kidney J 2017;10:560-3. [PMID: 28835817 DOI: 10.1093/ckj/sfx067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]